10 results about "Topical drug" patented technology

This invention provides a hydrogel for treating atopic dermatitis and its applications, relating to the field of biomedical technology. The hydrogel comprises SA, plasma water, L-G2, and / or FLA. Preliminary evaluation of the hydrogel was conducted through in vitro cytotoxicity and antibacterial performance tests, confirming its ability to inhibit Staphylococcus aureus and Escherichia coli. Simultaneously, the hydrogel exhibits low cytotoxicity, meeting the basic requirements for biomedical dressings. In animal experiments, by comparing skin lesions before and after treatment in AD mice, the hydrogel was observed to significantly improve skin lesions on the back of mice, demonstrating good anti-inflammatory effects. Pathological histological analysis showed that the hydrogel can reduce epidermal thickness, inhibit the increase in TNF-α levels induced by DNCB, and promote inflammation relief. Simultaneously, SA can provide a moist healing environment for skin wounds, helping to promote wound repair. Therefore, this hydrogel provides a new strategy for the treatment and management of AD and is expected to become a novel topical drug for AD treatment.

This invention belongs to the field of traditional Chinese medicine technology, and relates to a topical Chinese medicine composition, topical drug, topical patch, acupoint patch, and preparation method and application for treating nausea and vomiting caused by chemotherapy for intracranial tumors. The Chinese medicine composition consists of the following raw materials in parts by weight: 1-2 parts of Ligusticum chuanxiong, 1-2 parts of Gastrodia elata, 2-4 parts of Uncaria rhynchophylla, 1-2 parts of Citrus aurantium, 1-2 parts of Sinapis alba, 1-2 parts of Clematis chinensis, 0.5-1 part of Melia toosendan, 0.5-1 part of Panax ginseng, 1-2 parts of Pinellia ternata, 1-2 parts of Albizia julibrissin bark, 0.5-1 part of Lentinus edodes, and 1-2 parts of Astragalus membranaceus. This Chinese medicine composition has the effects of relieving nausea and vomiting, soothing the liver and strengthening the spleen, detoxifying and eliminating turbidity, calming the liver and extinguishing wind, and calming the mind and soothing the nerves. It not only effectively controls the nausea and vomiting symptoms caused by chemotherapy for intracranial tumors, but also harmonizes the body's Qi and organ functions. The Chinese medicine composition has a simple formula, widely available ingredients, and a simple preparation method; it is for topical application, convenient for clinical use, and has low adverse reactions.

The use of compositions in solid anhydrous form and in the form of a film, which can be reconstituted into semi-solid form at the time of topical application, as well as delivery systems for active ingredients or drugs, the related pharmaceutical compositions, the method for obtaining them and their use are described.

The present invention provides a topical pharmaceutical composition that contains a nonsteroidal anti-inflammatory drug, a lower alcohol, vitamin E derivatives, and water, without the harmful effects caused by high concentrations of alcohol, and without suppressing the precipitation of insoluble substances. [Solution] The topical pharmaceutical composition of the present invention contains (A) a nonsteroidal anti-inflammatory drug, (B) a nonionic surfactant with an HLB value greater than 6.5, (C) 30-45% by weight of a lower alcohol, (D) an antihistamine, (E) 0.1-2% by weight of vitamin E derivatives, (F) 3-6% by weight of monoterpenes, and (G) water.

To provide a topical pharmaceutical composition containing indomethacin, diclofenac sodium, felbinac, salicylic acids, or heparins, wherein irritation to the application site is reduced. [Solution] A topical pharmaceutical composition that contains component (A) and component (B) below, wherein component (A) is one or more selected from the group consisting of components (A-1) to (A-5) below, and which reduces irritation to the application site. Ingredient (A-1): Indomethacin Ingredient (A-2): Diclofenac sodium Ingredient (A-3): Felbinac Ingredients (A-4): Salicylic acids Ingredient (A-5): Heparinoid Ingredient (B): One or more selected from the group consisting of loxoprofen, its salts, and their hydrates.

To provide a topical pharmaceutical composition containing diclofenac in which crystal precipitation is suppressed. [Solution] A topical pharmaceutical composition comprising (A) one or more selected from the group consisting of loxoprofen, its salts and hydrates thereof, (B) one or more selected from the group consisting of diclofenac, its salts and hydrates thereof, and (C) a lower alcohol, wherein the content of the lower alcohol of (C) is 35% by mass or more and 60% by mass or less based on the total mass of the topical pharmaceutical composition, and the pH of the topical pharmaceutical composition is 5.0 to 7.5.

This invention discloses a recombinant human (or bovine) basic fibroblast growth factor gel with wound-healing and antibacterial functions, and its preparation method. Recombinant human (or bovine) basic fibroblast growth factor gel is a genetically engineered topical drug used clinically to promote healing of burn wounds, chronic wounds, and fresh wounds, with significant efficacy. However, its drawbacks include limited antibacterial properties and inability to be used simultaneously with chemical disinfectants such as iodine and ethanol, which, while promoting wound healing, are not conducive to controlling wound infection. Research has found that protamine sulfate or polylysine, with high safety and good antibacterial properties, can exert good antibacterial and anti-infection functions without negatively affecting the bioactivity and stability of recombinant human (or bovine) basic fibroblast growth factor. This represents an advanced method for preparing recombinant human (or bovine) basic fibroblast growth factor gel with wound-healing and antibacterial functions, enabling this type of drug to better exert its clinical effects and expand its application scope.

This invention belongs to the field of transdermal drug delivery nanocarrier technology, specifically relating to a nanoliposome using coconut oil as the lipid matrix and a specific Li medicinal herb composition (Alpinia oxyphylla + Artemisia argyi + Patchouli) as a natural penetration enhancer, and its preparation method. This product is a derivative of the core patent "A Natural Transdermal Permeation Enhancer Composition Based on Hainan Li Medicinal Herbs and Its Application" (patent application number: 2026106311990), used to significantly improve the transdermal efficiency and skin retention of the penetration enhancer composition, suitable for topical drugs and functional skin care products, realizing the industrialization extension of the core patent technology.

The present invention relates to methods and pharmaceutical compositions for treating conditions in non-human mammals, including seizures, idiopathic epilepsy, anxiety, noise aversion, and separation anxiety. The treatment involves administering cannabinoid compositions comprising at least one cannabinoid selected from cannabidiol (CBD), cannabidivarin (CBDV), cannabichromene (CBC), cannabigerol (CBG), cannabinol (CBN), and tetrahydrocannabivarin (THCV). Specific embodiments comprise CBD isolate nano-particles with purity greater than 99% of total cannabinoids and particle sizes less than 100 nanometers, suspended in oil-based media, essentially free of tetrahydrocannabinol (THC). Methods include acute treatment for noise aversion administered immediately prior to or during noise events, and daily administration for separation anxiety management. A pharmaceutical composition comprising CBD, CBDV, and CBC in a 5:1:1 weight ratio for treating seizures and idiopathic epilepsy is disclosed. The compositions may be administered orally, sublingually, or topically at dosages of 0.1 to 10 mg per kg body weight in cats, dogs, and horses.

To provide a topical pharmaceutical composition containing loxoprofen and felbinac, wherein crystal precipitation is suppressed. [Solution] (A) One or more selected from the group consisting of loxoprofen, its salts and hydrates thereof, (B) One or more selected from the group consisting of felbinac, its salts and hydrates thereof, (C) One or more surfactants having a hydrocarbon chain structure and a polyoxyethylene structure, wherein the ratio of the average number of added moles of the polyoxyethylene chain to the number of carbon atoms of the hydrocarbon chain is 2.0 or less, and (D) Lower alcohol. An external pharmaceutical composition containing a lower alcohol, a surfactant, and a pH that meets predetermined conditions.